JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265774

Human IFNE (IFNE1) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

IFNE KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 28 bp deletion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human IFNE (IFNE1) knockout HeLa cell line (AB265774)
  • Sanger seq

Unknown

Sanger Sequencing - Human IFNE (IFNE1) knockout HeLa cell line (AB265774)

Allele-2 : 28 bp deletion in exon 1.

Sanger Sequencing - Human IFNE (IFNE1) knockout HeLa cell line (AB265774)
  • Sanger seq

Unknown

Sanger Sequencing - Human IFNE (IFNE1) knockout HeLa cell line (AB265774)

Allele-1 : 1 bp insertion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 28 bp deletion in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265774-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265774-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265774 Human IFNE (IFNE1) knockout HeLa cell line", "number":"AB265774-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265774-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265774-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265774 Human IFNE (IFNE1) knockout HeLa cell line", "number":"AB265774-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265774-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265774 Human IFNE (IFNE1) knockout HeLa cell line", "number":"AB265774-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265774-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265774 Human IFNE (IFNE1) knockout HeLa cell line", "number":"AB265774-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
IFNE
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The protein IFNE also known as Interferon epsilon plays an important role in the immune response. It has a molecular mass of about 22-24 kDa and is mostly expressed in mucosal tissues particularly in the reproductive tract. Unlike other interferons IFNE expression does not get induced during infection reflecting its unique role in immune regulation. Scientists recognize it for its involvement in antiviral and antibacterial defense mechanisms at epithelial surfaces.
Biological function summary

IFNE contributes to the innate immune system by modulating immune responses without being part of a larger protein complex. It activates signaling pathways that result in the production of other immune response mediators. This protein supports the barrier function of epithelial cells enhancing the organism's ability to fend off infectious agents. Additionally it helps maintain homeostatic conditions in mucosal tissues by managing inflammation.

Pathways

IFNE integrates into the broader interferon signaling pathway and the JAK-STAT signaling pathway. These pathways mediate various cellular responses to external stimuli including pathogen infections. IFNE interacts with sister proteins such as IFN-alpha and IFN-beta in these pathways to drive protective responses and regulate inflammation. Understanding its pathway involvement assists researchers in designing targeted therapies for immune modulation.

Studies indicate that IFNE might influence conditions like cervical cancer and recurrent viral infections. Research shows its interaction with HPV-related proteins affects the progression of cervical cancer. In viral infections IFNE works with IFN-alpha to mediate the immune response reducing viral load and potentially altering disease outcomes. This makes it a point of interest in the development of treatments for infections and certain cancers.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com